Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma

BACKGROUND: Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. Intrinsic and acquired resistance to pemetrexed is common, but its biological basis is obscure. Here we report for the firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Røe, Oluf Dimitri, Szulkin, Adam, Anderssen, Endre, Flatberg, Arnar, Sandeck, Helmut, Amundsen, Tore, Erlandsen, Sten Even, Dobra, Katalin, Sundstrøm, Stein Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414492/
https://www.ncbi.nlm.nih.gov/pubmed/22905093
http://dx.doi.org/10.1371/journal.pone.0040521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414492/
https://www.ncbi.nlm.nih.gov/pubmed/22905093
http://dx.doi.org/10.1371/journal.pone.0040521

Ejemplares similares